Literature DB >> 21241732

Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes.

Liguo Niu1, James M Termini, Saravana K Kanagavelu, Sachin Gupta, Morgane M Rolland, Viraj Kulkarni, George N Pavlakis, Barbara K Felber, James I Mullins, Margaret A Fischl, Geoffrey W Stone.   

Abstract

BACKGROUND: Dendritic cell (DC) therapy is a promising technology for the treatment of HIV infected individuals. HIV-1 Gag- and Nef RNA-loaded DC have previously been shown to induce immune responses ex vivo following coculture with autologous lymphocytes. However, polyfunctionality and memory responses following coculture have not been evaluated. In addition, little is known regarding whether specific HIV-1 proteome components, such as highly conserved regions of the HIV-1, could enhance clinical responses following DC therapy. METHODOLOGY AND PRINCIPAL
FINDINGS: To determine the breadth of the immune responses to antigen loaded DC, we analyzed polyfunctional T cell response ex vivo to Gag RNA loaded DC. Blood samples were used to generate monocyte derived DC, which were then matured and cocultured with autologous lymphocytes. We found that cytokine-matured DC loaded with Gag RNA was able to induce Gag-specific IFN-γ and IL-2 responses after a 12-day coculture. We characterized these responses by polyfunctional intracellular cytokine staining and evaluation of T cell memory phenotypes. Central memory CD8+ T cells were induced ex vivo after DC coculture from each of 3 patients, and the effector memory pool was increased by DC coculture from 2 patients. We also observed a decrease in the terminal effector and intermediate CD8+ T cell pool and an increase in the naïve/other population. There was a reduction in terminal effector and intermediate CD4+ T cells, and a corresponding increase in naïve/other CD4+ T cells. Finally, we evaluated conserved regions of Gag as a novel DC therapy immunogen and found that a conserved element (CE) p24 Gag antigen elicited IFN-γ and IL-2 responses comparable to those induced by a full-length Gag antigen.
CONCLUSIONS: We showed that RNA-loaded DC therapy induced a polyfunctional T cell response ex vivo, supporting the use of such DC-therapy for HIV infection. However, the central and effector memory phenotypes of T cells did not appear to be enhanced during coculture with Gag RNA-loaded DC. Furthermore, comparable antigen-specific responses were induced in HIV infected individuals using full-length Gag or only conserved elements of the Gag p24 protein. This indicates that immune responses can be focused onto the conserved elements of Gag in the absence of other Gag components.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21241732      PMCID: PMC3046258          DOI: 10.1016/j.vaccine.2010.12.131

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

1.  Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1.

Authors:  Shinichiro Fuse; Ching-Yi Tsai; Michael J Molloy; S Rameeza Allie; Weijun Zhang; Hideo Yagita; Edward J Usherwood
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 2.  Mucosal immune dysfunction in AIDS pathogenesis.

Authors:  Mirko Paiardini; Ian Frank; Ivona Pandrea; Cristian Apetrei; Guido Silvestri
Journal:  AIDS Rev       Date:  2008 Jan-Mar       Impact factor: 2.500

Review 3.  Dendritic cell-based human immunodeficiency virus vaccine.

Authors:  C R Rinaldo
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

4.  Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals.

Authors:  Ellen R Van Gulck; Guido Vanham; Leo Heyndrickx; Sandra Coppens; Katleen Vereecken; Derek Atkinson; Eric Florence; Ilse Kint; Zwi Nisan Berneman; Viggo Van Tendeloo
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

5.  HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals.

Authors:  Sandra A Calarota; Andrea Foli; Renato Maserati; Fausto Baldanti; Stefania Paolucci; Mary A Young; Christos M Tsoukas; Julianna Lisziewicz; Franco Lori
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

6.  Rare HLA drive additional HIV evolution compared to more frequent alleles.

Authors:  Christine M Rousseau; David W Lockhart; Jennifer Listgarten; Stephen N Maley; Carl Kadie; Gerald H Learn; David C Nickle; David E Heckerman; Wenjie Deng; Christian Brander; Thumbi Ndung'u; Hoosen Coovadia; Philip J R Goulder; Bette T Korber; Bruce D Walker; James I Mullins
Journal:  AIDS Res Hum Retroviruses       Date:  2009-03       Impact factor: 2.205

7.  Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10.

Authors:  Sandrine Buisson; Adel Benlahrech; Brian Gazzard; Frances Gotch; Peter Kelleher; Steven Patterson
Journal:  J Infect Dis       Date:  2009-06-15       Impact factor: 5.226

8.  Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge.

Authors:  Joseph J Mattapallil; Daniel C Douek; Alicia Buckler-White; David Montefiori; Norman L Letvin; Gary J Nabel; Mario Roederer
Journal:  J Exp Med       Date:  2006-05-30       Impact factor: 14.307

9.  Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy.

Authors:  Manuela Rehr; Julia Cahenzli; Anna Haas; David A Price; Emma Gostick; Milo Huber; Urs Karrer; Annette Oxenius
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

Review 10.  HIV-1 group M conserved elements vaccine.

Authors:  Morgane Rolland; David C Nickle; James I Mullins
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

View more
  16 in total

Review 1.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

2.  HIV-1 conserved-element vaccines: relationship between sequence conservation and replicative capacity.

Authors:  Morgane Rolland; Siriphan Manocheewa; J Victor Swain; Erinn C Lanxon-Cookson; Moon Kim; Dylan H Westfall; Brendan B Larsen; Peter B Gilbert; James I Mullins
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

Review 3.  Myeloid dendritic cells in HIV-1 infection.

Authors:  Nina Derby; Elena Martinelli; Melissa Robbiani
Journal:  Curr Opin HIV AIDS       Date:  2011-09       Impact factor: 4.283

4.  Preparing for the availability of a partially effective HIV vaccine: some lessons from other licensed vaccines.

Authors:  Robert T Chen; Dale J Hu; Eileen Dunne; Michael Shaw; James I Mullins; Supachai Rerks-Ngarm
Journal:  Vaccine       Date:  2011-07-13       Impact factor: 3.641

5.  Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes.

Authors:  Rong Wang; Andrew Freywald; Yue Chen; Jianqing Xu; Xin Tan; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2014-09-08       Impact factor: 11.530

6.  Increased sequence coverage through combined targeting of variant and conserved epitopes correlates with control of HIV replication.

Authors:  Justine Sunshine; Moon Kim; Jonathan M Carlson; David Heckerman; Julie Czartoski; Stephen A Migueles; Janine Maenza; M Juliana McElrath; James I Mullins; Nicole Frahm
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

7.  Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design.

Authors:  Pratima Kunwar; Natalie Hawkins; Warren L Dinges; Yi Liu; Erin E Gabriel; David A Swan; Claire E Stevens; Janine Maenza; Ann C Collier; James I Mullins; Tomer Hertz; Xuesong Yu; Helen Horton
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

8.  Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV gag p24 protein.

Authors:  Leonia Bozzacco; Haiqiang Yu; Jörn Dengjel; Christine Trumpfheller; Henry A Zebroski; Nawei Zhang; Victoria Küttner; Beatrix M Ueberheide; Haiteng Deng; Brian T Chait; Ralph M Steinman; Svetlana Mojsov; David Fenyö
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

9.  HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice.

Authors:  Viraj Kulkarni; Margherita Rosati; Antonio Valentin; Brunda Ganneru; Ashish K Singh; Jian Yan; Morgane Rolland; Candido Alicea; Rachel Kelly Beach; Gen-Mu Zhang; Sylvie Le Gall; Kate E Broderick; Niranjan Y Sardesai; David Heckerman; Beatriz Mothe; Christian Brander; David B Weiner; James I Mullins; George N Pavlakis; Barbara K Felber
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

10.  Fitness costs of mutations at the HIV-1 capsid hexamerization interface.

Authors:  Siriphan Manocheewa; J Victor Swain; Erinn Lanxon-Cookson; Morgane Rolland; James I Mullins
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.